In a town hall-style teleconference held August 26, Genzyme Corp.'s long-time CEO Henri Termeer admitted that the shutdown of its Allston Landing, MA-based manufacturing facility because of viral contamination earlier this summer resulted in "many, big expensive lessons." We are only beginning to know just how expensive the tutorial could be.
In early August, the company revealed 2009 sales of its blockbuster Gaucher disease drug imiglucerase (Cerezyme) would be reduced from...